Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation in first remission

J M Rowe1

  • 1Hematology Unit, University of Rochester School of Medicine and Dentistry, Strong Memorial Hospital, NY 14642, USA.

Leukemia
|May 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.

Bone marrow transplantation·2024
Same author

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Bone marrow transplantation·2017
Same author

The NIST Cold Neutron Research Facility.

Journal of research of the National Institute of Standards and Technology·2017
Same author

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Blood cancer journal·2016
Same author

Materials Research With Neutrons at NIST.

Journal of research of the National Institute of Standards and Technology·2016

Allogeneic stem cell transplants show similar survival rates for acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) in first remission. Further research is needed to confirm the benefits of autologous transplantation for ALL.

Area of Science:

  • Hematology
  • Oncology
  • Transplant Immunology

Background:

  • Allogeneic bone marrow transplantation (BMT) is a widely used treatment for acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
  • Existing data suggest comparable outcomes between AML and ALL for allogeneic transplantation in first and second remission.
  • The efficacy of autologous stem-cell transplantation (ASCT) for ALL, particularly in first remission, requires further investigation.

Purpose of the Study:

  • To compare the disease-free survival rates of allogeneic BMT in AML and ALL patients.
  • To evaluate the current evidence for ASCT in ALL and identify the need for further studies.
  • To determine the clinical benefit of ex vivo bone marrow transplantation for ALL.

Main Methods:

  • Comparative analysis of published data on allogeneic BMT for AML and ALL.

Related Experiment Videos

  • Review of existing studies on autologous stem-cell transplantation for ALL.
  • Identification of the need for prospective randomized trials for ex vivo BMT in ALL.

    • Main Results:

    • Disease-free survival rates for AML in first remission (40-65%) are comparable to those for ALL in first remission.
    • Allogeneic transplant data for ALL in second remission mirror those for AML.
    • The efficacy of ASCT for ALL in first remission remains unproven, necessitating larger multicenter studies.

    Conclusions:

    • Allogeneic transplantation offers similar survival benefits for AML and ALL in comparable remission states.
    • Prospective randomized trials, including those with genetic marking for ex vivo BMT in ALL, are essential to establish clinical benefit.
    • Further research is crucial to validate ASCT efficacy in ALL and guide treatment decisions.